LIFEVANTAGE CORP Operating Lease, Expense
LIFEVANTAGE CORP (LFVN) reported Operating Lease, Expense of $500.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-05-06
- LIFEVANTAGE CORP operating lease, expense for the quarter ending 2026-03-31 was $500.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP operating lease, expense for the quarter ending 2025-12-31 was $500.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP operating lease, expense for the quarter ending 2025-09-30 was $500.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP operating lease, expense for the quarter ending 2025-03-31 was $500.00K, a 0.00% change year-over-year.
- LIFEVANTAGE CORP operating lease, expense for fiscal 2022 was $3.20M, a 11.11% decline from fiscal 2021.
- LIFEVANTAGE CORP operating lease, expense for fiscal 2021 was $3.60M, a 33.33% increase from fiscal 2020.
- LIFEVANTAGE CORP operating lease, expense for fiscal 2020 was $2.70M.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-06 | $1.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.40M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $500.00K 10-Q · filed 2026-02-04 | $900.00K 10-Q · filed 2026-02-04 | ||
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-04 | |||
| 2025-03-31 | $500.00K 10-Q · filed 2026-05-06 | $1.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.50M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $500.00K 10-Q · filed 2026-02-04 | $1.00M 10-Q · filed 2026-02-04 | ||
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-04 | |||
| 2024-03-31 | $500.00K 10-Q · filed 2025-05-06 | $1.00M derived: sum of 2 quarters · filed 2025-05-06 | $1.60M 10-Q · filed 2025-05-06 | |
| 2023-12-31 | $500.00K 10-Q · filed 2025-02-05 | $1.10M 10-Q · filed 2025-02-05 | ||
| 2023-09-30 | $600.00K 10-Q · filed 2024-10-29 | |||
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-02 | $1.40M derived: sum of 2 quarters · filed 2024-05-02 | $2.20M 10-Q · filed 2024-05-02 | $2.80M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $800.00K 10-Q · filed 2024-01-30 | $1.50M 10-Q · filed 2024-01-30 | $2.20M derived: sum of 3 quarters · filed 2024-01-30 | $3.00M derived: sum of 4 quarters · filed 2024-01-30 |
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-09 | $1.40M derived: sum of 2 quarters · filed 2023-11-09 | $2.20M derived: sum of 3 quarters · filed 2023-11-09 | $3.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-23 | $1.50M derived: sum of 2 quarters · filed 2023-05-04 | $2.30M derived: sum of 3 quarters · filed 2023-05-04 | $3.20M 10-K · filed 2022-08-23 |
| 2022-03-31 | $800.00K 10-Q · filed 2023-05-04 | $1.60M derived: sum of 2 quarters · filed 2023-05-04 | $2.50M 10-Q · filed 2023-05-04 | $3.20M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $800.00K 10-Q · filed 2023-02-02 | $1.60M 10-Q · filed 2023-02-02 | $2.40M derived: sum of 3 quarters · filed 2023-02-02 | $3.20M derived: sum of 4 quarters · filed 2023-02-02 |
| 2021-09-30 | $800.00K 10-Q · filed 2022-11-02 | $1.60M derived: sum of 2 quarters · filed 2022-11-02 | $2.40M derived: sum of 3 quarters · filed 2022-11-02 | $3.20M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-23 | $1.60M derived: sum of 2 quarters · filed 2022-08-23 | $2.40M derived: sum of 3 quarters · filed 2022-08-23 | $3.60M 10-K · filed 2022-08-23 |
| 2021-03-31 | $800.00K 10-Q · filed 2022-05-03 | $1.60M derived: sum of 2 quarters · filed 2022-05-03 | $2.80M 10-Q · filed 2022-05-03 | $3.50M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-12-31 | $800.00K 10-Q · filed 2022-02-01 | $2.00M 10-Q · filed 2022-02-01 | $2.70M derived: sum of 3 quarters · filed 2022-08-23 | $3.40M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-09-30 | $1.20M 10-Q · filed 2021-11-04 | $1.90M derived: sum of 2 quarters · filed 2022-08-23 | $2.60M derived: sum of 3 quarters · filed 2022-08-23 | $3.30M derived: sum of 4 quarters · filed 2022-08-23 |
| 2020-06-30 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-08-23 | $1.40M derived: sum of 2 quarters · filed 2022-08-23 | $2.10M derived: sum of 3 quarters · filed 2022-08-23 | $2.70M 10-K · filed 2022-08-23 |
| 2020-03-31 | $700.00K 10-Q · filed 2021-04-29 | $1.40M derived: sum of 2 quarters · filed 2021-04-29 | $2.00M 10-Q · filed 2021-04-29 | |
| 2019-12-31 | $700.00K 10-Q · filed 2021-02-02 | $1.30M 10-Q · filed 2021-02-02 | ||
| 2019-09-30 | $700.00K 10-Q · filed 2020-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |